Medivir Q1 Revenue Up, EBITDA Loss Narrows

Medivir reported Q1 revenue of SEK 1 million, with EBITDA loss narrowing to SEK 8.80 million.
Adjusted free cash flow was negative SEK 13 million, while cash and cash equivalents rose to SEK 149.1 million at quarter‑end.
In February, the company completed a directed share issue of SEK 45 million, which CEO Jens Lindberg said strengthens finances for clinical programs.
Medivir will launch phase‑2 studies for MIV‑711 (Osteogenesis Imperfecta) and fostrox (second‑line liver cancer); MIV‑701 results are expected in Q4 2026.